- Home
- TRS vs EYPT Comparison
TRS vs EYPT Comparison
Compare TRS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRS | EYPT |
|---|---|---|
| Founded | 1986 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2004 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TRS | EYPT |
|---|---|---|
| Price | $41.37 | $12.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $41.50 | $31.80 |
| AVG Volume (30 Days) | 350.1K | ★ 941.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 21.40 | N/A |
| Revenue | ★ $645,720,000.00 | $7,539,000.00 |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $4.27 | $3,115.57 |
| P/E Ratio | $1.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.57 | $8.37 |
| 52 Week High | $43.72 | $19.11 |
Technical Indicators
Market Signals| Indicator | TRS | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.56 | 50.07 |
| Support Level | $35.40 | $12.58 |
| Resistance Level | $41.84 | $14.58 |
| Average True Range (ATR) | 1.15 | 0.72 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 89.97 | 53.85 |
Price Performance
Historical ComparisonAbout TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.